Sign In
Buy BLRX
$3.28
-0.110 (-3.24%)
At Close: Jun 03, 2026
BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript
10:47am, Wednesday, 27'th May 2026
BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
07:00am, Wednesday, 27'th May 2026
- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) - - Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-
TEL AVIV, Israel and OSLO, Norway, May 22, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
07:00am, Wednesday, 20'th May 2026
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 20, 2026 /PRNewswire/ -- BioLineRx Ltd.
New preclinical data further demonstrate GLIX1's robust efficacy in a dose-dependent manner, with strong anti-tumor activity observed even at the lowest doses tested Results highlight GLIX1's potentia
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
07:00am, Tuesday, 28'th Apr 2026
Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer Center Data from the Ph
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
02:30am, Wednesday, 08'th Apr 2026
OSLO, Norway--(BUSINESS WIRE)--Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced the initiation of a first-in-human Phase 1/2a clinical t
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
07:00am, Thursday, 26'th Mar 2026
GLIX1, a TET2 activator , is a first -in- class , oral, small molecule targeting DNA damage response in glioblastoma and other cancers GLIX1 has demonstrated potent anti-tumor activity in multip
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript
10:43am, Monday, 23'rd Mar 2026
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
07:00am, Monday, 23'rd Mar 2026
- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month - - GLIX1 is positioned to potentially address unmet needs for novel and more effect
BioLineRx (BLRX) Projected to Post Quarterly Earnings on Monday
01:04am, Saturday, 21'st Mar 2026
BioLineRx (NASDAQ: BLRX - Get Free Report) is expected to release its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.50) per sha
Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings
02:45am, Friday, 20'th Mar 2026
BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably.
BioLineRx to Report 2025 Annual Results on March 23, 2026
07:00am, Monday, 16'th Mar 2026
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, March 16, 2026 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript
10:53am, Monday, 24'th Nov 2025
BioLineRx Ltd. ( BLRX ) Q3 2025 Earnings Call November 24, 2025 8:30 AM EST Company Participants Irina Koffler - Managing Director Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Monday, 24'th Nov 2025
- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers - - Phase 1/2a clinical trial
